The Fund invested in BioVercys 32,6M CHF = 35M UD$ and got perhaps 10%-15% (?) of the company. Today the market cap of ATH was US$16,38M, much less than it has cash and also much less than what the investment by the Fund was to get 10-15 % (?) of BioVercys.
I do not think the experts of the Fund made any big mistake when they evaluated the value of that company. I would expect the corresponding valuation when and if the Fund evaluates PBT2 and ATH as a possible investments.
Comparison between MC and the investment of the Fund
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(10.0%) |
Mkt cap ! $23.60M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $1.436K | 319.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 92514720 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 29904675 | 20 |
View Market Depth
| Last trade - 14.52pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
-0.001 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 500000 | ||
| Last updated 15.07pm 14/06/2024 ? | |||||
| ATH (ASX) Chart |